Medroxyprogesterone in metastatic renal cell carcinoma.
We have described a patient in whom complete regression of pulmonary metastases from renal cell carcinoma (RCC) followed treatment with medroxy-progesterone acetate (Depo-Provera). Although the reported rate of objective response to progesterone therapy in RCC is only 10% to 15%, the occasionally dramatic results, especially in men, warrant a trial of this agent. Other more toxic agents have consistently failed to provide significant responses.
D000230:Adenocarcinoma / Q000556:secondary*; D000368:Aged; D006801:Humans; D007680:Kidney Neoplasms / Q000601:surgery; D008175:Lung Neoplasms / Q000556:secondary*; D008297:Male; D008525:Medroxyprogesterone / Q000627:therapeutic use*; D009392:Nephrectomy
D008525:Medroxyprogesterone